Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2026-03-25

Clinical Trial Update: HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903 [Phase 2]

View source ↗

Summary

Phase 2 trial of HIV antigen-specific T-cells targeting conserved epitopes (HST-NEETs) for HIV-associated lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • HST-NEETs

Snippet

Sponsor: Catherine Bollard | Conditions: HIV Associated Lymphoma | Phase 2 | Status: COMPLETED